Stockscreener 앱 받기
10.33
4.44%
-0.48
시간 외 거래:
10.36
0.03
+0.29%
전일 마감가:
$10.81
열려 있는:
$10.63
하루 거래량:
8.50M
Relative Volume:
3.71
시가총액:
$700.63M
수익:
$65,400
순이익/손실:
$-46.34M
주가수익비율:
-11.23
EPS:
-0.92
순현금흐름:
$-38.74M
1주 성능:
-11.25%
1개월 성능:
-8.42%
6개월 성능:
+1.67%
1년 성능:
+158.25%
1일 변동 폭
$9.8192
$11.23
1주일 범위
$9.605
$12.48
52주 변동 폭
$3.61
$17.43
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
10.33 | 889.43M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
HC Wainwright Maintains Buy Rating on Cormedix, Adjusts Price Target to $17.00 - AInvest
Unraveling the Drop in CorMedix (CRMD.O): A Technical and Market Flow Deep Dive - AInvest
Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... By GuruFocus - Investing.com Canada
CorMedix signs agreement to acquire Melinta for $300m - Yahoo Finance
CorMedix Inc. Reports Strong Q2 2025 Results - TipRanks
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
Transcript : CorMedix Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CorMedix: Q2 Earnings Snapshot - Stamford Advocate
Cormedix’s Strategic Growth Potential Boosted by Melinta Therapeutics Acquisition - TipRanks
CorMedix (CRMD.O) Suffers Sharp Intraday Drop: What’s the Story Behind? - AInvest
CRMD Faces Major Legal Battle - StocksToTrade
CorMedix Surpasses Expectations with Q2 Earnings Surge - AInvest
CorMedix Forecasts FY25 Pro Forma Revenue of $305M-$335M - AInvest
M&A News: CorMedix Stock (CRMD) Plunges 11% Despite $300M Melinta Deal - TipRanks
CorMedix buys Melinta Therapeutics for $300M - ROI-NJ
Cormedix Inc. shares fall 11.38% intraday after announcing $260M acquisition of Melinta Therapeutics, raising dilution and financing concerns. - AInvest
CorMedix To Acquire Melinta Therapeutics In $300 Mln Deal To Expand Infectious Disease Portfolio - Nasdaq
CorMedix to Buy Melinta Therapeutics for $300 Million - The Wall Street Journal
CorMedix to acquire Melinta Therapeutics for $300M - TipRanks
CorMedix Inc. SEC 10-Q Report - TradingView
CorMedix Announces Merger Agreement with Melinta Therapeutics - TipRanks
CorMedix To Acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence In Acute Care Settings - TradingView
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
CorMedix reports Q2 EPS 28c, consensus 19c - TipRanks
CorMedix earnings beat by $0.12, revenue topped estimates - Investing.com Canada
CorMedix to acquire Melinta Therapeutics in $300 million deal - Investing.com
CorMedix Acquires Seven Drug Products, Expands Revenue to $305-335mln by 2025. - AInvest
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership - Business Wire
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings - The Manila Times
Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
$300M CorMedix-Melinta Deal Creates Powerhouse with $335M Revenue Potential, 7 Acute Care Products - Stock Titan
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises - The Globe and Mail
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
iShares Morningstar Small-Cap ETF Holdings Could Mean 18% Gain Potential - AInvest
What makes CorMedix Inc. stock price move sharplyConsistent double returns - Jammu Links News
What drives CorMedix Inc. stock priceMarket-leading capital gains - Jammu Links News
What catalysts could drive CorMedix Inc. stock higher in 2025Track high-yield stocks before they peak - Jammu Links News
When is CorMedix Inc. stock expected to show significant growthExtraordinary market timing - Jammu Links News
Should I hold or sell CorMedix Inc. stock in 2025Unlock steady growth with low-risk stocks - Jammu Links News
How does CorMedix Inc. generate profit in a changing economyExceptional return forecasts - Jammu Links News
How many analysts rate CorMedix Inc. as a “Buy”Achieve consistent double-digit growth - Jammu Links News
Is CorMedix Inc. stock overvalued or undervaluedExplosive capital gains - Jammu Links News
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):